44 Wealth Management LLC Cuts Stock Holdings in Bristol Myers Squibb Company $BMY

44 Wealth Management LLC lowered its position in Bristol Myers Squibb Company (NYSE:BMY) by 23.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,227 shares of the biopharmaceutical company’s stock after selling 13,853 shares during the period. Bristol Myers Squibb comprises about 0.9% of 44 Wealth Management LLC’s portfolio, making the stock its 27th largest position. 44 Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $2,682,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Van Diest Capital LLC bought a new position in shares of Bristol Myers Squibb in the first quarter worth $352,000. Bradley Foster & Sargent Inc. CT raised its holdings in shares of Bristol Myers Squibb by 0.8% in the 1st quarter. Bradley Foster & Sargent Inc. CT now owns 38,778 shares of the biopharmaceutical company’s stock valued at $2,352,000 after acquiring an additional 308 shares in the last quarter. Lombard Odier Asset Management Switzerland SA boosted its position in shares of Bristol Myers Squibb by 29.2% during the 1st quarter. Lombard Odier Asset Management Switzerland SA now owns 83,569 shares of the biopharmaceutical company’s stock valued at $5,068,000 after acquiring an additional 18,900 shares during the last quarter. Aristotle Atlantic Partners LLC bought a new stake in shares of Bristol Myers Squibb during the 1st quarter valued at about $1,128,000. Finally, Waverly Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 49.6% during the first quarter. Waverly Advisors LLC now owns 85,970 shares of the biopharmaceutical company’s stock worth $5,214,000 after purchasing an additional 28,502 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 0.9%

Shares of NYSE BMY opened at $62.05 on Friday. The stock has a market capitalization of $126.70 billion, a P/E ratio of 17.43, a PEG ratio of 0.18 and a beta of 0.23. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The firm’s 50 day simple moving average is $57.49 and its two-hundred day simple moving average is $58.03. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the firm earned $1.80 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title
• Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title
• Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title
• Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title
• Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BMY shares. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Bank of America dropped their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.